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Abstract
Alternative splicing and post-translational modifications are processes that give rise to the complexity of the proteome. The
nuclear ATF7 and ATF2 (activating transcription factor) are structurally homologous leucine zipper transcription factors
encoded by distinct genes. Stress and growth factors activate ATF2 and ATF7 mainly via sequential phosphorylation of two
conserved threonine residues in their activation domain. Distinct protein kinases, among which mitogen-activated protein
kinases (MAPK), phosphorylate ATF2 and ATF7 first on Thr71/Thr53 and next on Thr69/Thr51 residues respectively, resulting
in transcriptional activation. Here, we identify and characterize a cytoplasmic alternatively spliced isoform of ATF7. This
variant, named ATF7-4, inhibits both ATF2 and ATF7 transcriptional activities by impairing the first phosphorylation event
on Thr71/Thr53 residues. ATF7-4 indeed sequesters the Thr53-phosphorylating kinase in the cytoplasm. Upon stimulus-
induced phosphorylation, ATF7-4 is poly-ubiquitinated and degraded, enabling the release of the kinase and ATF7/ATF2
activation. Our data therefore conclusively establish that ATF7-4 is an important cytoplasmic negative regulator of ATF7 and
ATF2 transcription factors.
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Introduction
The characterization of cellular pathways leading to all the post-
translational modifications of a protein is essential to understand the
molecular mechanisms regulating its functions. Crosstalks between
different types of such modifications are an emerging theme in
eukaryotic biology. Thus, examples of multiple connections between
phosphorylation, sumoylation and ubiquitination have been described
(for a review see [1]). Within the AP-1 transcription factors family, the
ATF2, ATF7 and CREB5 compose a subfamily based on sequence
conservation [2,3,4,5]. The transcriptional activation and DNA-
binding domains of ATF2 and ATF7 factors are highly conserved and
their specificity is mainly governed by post-translational modifications
and interactions with specific cofactors [6,7,8,9]. ATF2 is a protein
that displays diverse, tissue-dependent functions [10,11]. For instance,
ATF2 has been implicated in malignant and non-malignant skin
tumor development [12,13]. ATF2 also elicits a suppressor function in
mammary tumors [14], and mediates lipopolysaccharide-induced
transcription in macrophage cells [15].
ATF7 shares a considerable sequence homology with ATF2,
especially within the C-terminal DNA-binding/dimerization
domain and the N-terminal activation domain. This latter region
includes a critical zinc-binding element and two conserved
threonine residues (Thr51 and Thr53 corresponding to the
Thr69 and Thr71 homologues in ATF2). Different mitogen-
activated protein kinases (MAPK), particularly members of JNK
and p38 families, specifically phosphorylate these conserved
threonine residues of ATF2 and ATF7 leading to transcriptional
activation [16,17,18,19,20,21,22,23,24,25]. These phosphoryla-
tion events are essential for ATF7/ATF2 proteins function in vivo,
since Atf2
A/A mice, carrying mutations in these critical phosphor-
ylation sites, have a strong phenotype, identical to that seen upon
deletion of the DNA-binding domain [26,27]. Combining this
mutant with a knockout of ATF7 (Atf7
2/2) results in embryonic
lethality with severe abnormalities in the developing liver and
heart [26]. Moreover, Atf7
2/2 mice exhibit abnormal behaviors
and increased serotonin 5-HT receptor 5B (Htr5b) mRNA levels
in the dorsal raphe nuclei [28].
Alternative splicing of pre-mRNAs accounts for a large
proportion of proteomic complexity [29,30]. New splicing events
occurring within protein coding regions potentially alter the
biological function of the gene by expressing polypeptides with
novel functions [31,32]. Until now, the ATF7 transcription factor
subfamily was known to include at least two major proteins (ATF7-
1, ATF7-2) translated from alternatively spliced messengers
transcribed from a unique gene [33]. In the present study, we
report the identification and functional characterization of a short
alternatively spliced variant of ATF7 that is highly conserved
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RNA encodes a functional C-terminally truncated protein, ATF7-4,
whose intracellular location is restricted to the cytoplasm and which
downregulatesthetranscriptionalactivityofboth nuclearATF7 and
ATF2 transcription factors. We show that, under resting conditions,
ATF7-4 interacts in the cytoplasm with a kinase. Our data are
compatible with the idea that this kinase is responsible for the
priming phosphorylation event of the ATF7/ATF2 factors. In
contrast, a stimulus-induced phosphorylation of ATF7-4 leads to its
poly-ubiquitination and degradation by a proteasome 26S-
dependent pathway, enabling ATF7/ATF2 activation.
Results
Identification of a new ATF7 isoform
To look for new ATF7 isoforms that could participate in the
ATF7-dependent transcriptional regulation, we performed an-
chored RT-PCR on HeLa mRNA using oligo-(dT) and ATF7-
specific primers overlapping the translation initiation codon. We
obtained a short amplification product (809 bp) that encodes an
ATF7 alternatively spliced isoform of 117 residues designated
ATF7-4 (following the ATF7 nomenclature). However, no such
short product was amplified in mouse 3T3 fibroblasts under the
same conditions (data not shown). To understand the existence of
this new isoform, a comparative analysis of human and mouse
ATF7 gene sequences was performed (Figure 1A). First, we
observed that the human exon 4 is followed by a potential exon,
referred to as exon 4a, that contains an open-reading frame
encoding 29 amino acids. Moreover, this newly identified exon
that is not found in the mouse gene displays a polyadenylation
sequence (AATAAA) at its 39 border. The inclusion of exon 4a is
enabled when the splice donor site (DS) of exon 4 is not used. As a
result, a short transcript encoding ATF7-4 is generated. Interest-
ingly, examination of the nucleotide sequence of the ATF7 gene
also revealed in exon 5 an alternative splice donor site (DS1),
absent in the mouse gene, that can be used in place of the donor
site of the exon 5a (DS2) (Figure 1A). The use of DS1 gives rise to
the human ATF7-1 isoform. By contrast, the ATF7-2 variant
encompassing exons 5 and 5a is expressed in both human and
mouse. Thus, three major different transcripts are encoded in
Figure 1. Identification of ATF7-4 as a novel alternatively spliced ATF7 isoform. (A) The structure of the ATF7 gene, a member of the ATF2/
ATF7/CREB5 family, is shown schematically: the twelve exons are indicated by numbered boxes, and an alternative splicing region encompassing
exons 4 to 6 is compared between human and mouse species. The sequences of the donor (DS) and acceptor (AS) sites for splicing are indicated,
capital and small letters corresponding to the exonic and the intronic parts respectively. 4a and 5a are alternatively included exons adjacent to exons
4 and 5 respectively. The start codon, stop codons and polyadenylation sites are shown. (B) Schematic representation of the exonic structure of three
ATF7 alternatively spliced isoforms. The regions encoding the zinc finger (ZnF)/activation domain (AD) or the nuclear localization signal (NLS)/basic
region-leucine zipper (b-Zip) are indicated. ‘‘+’’ indicates that the proteins are encoded, either in human or in mouse species. (C) Amino acid sequence
alignment of ATF7-4 exon 4 and specific exon 4a of a series of mammalian species. A conserved C-terminal hydrophobic domain is highlighted.
doi:10.1371/journal.pone.0023351.g001
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encoded in mouse (Figure 1B).
The ATF7-4 protein contains the common ATF7 N-terminal
moiety (88 residues) encompassing the transcriptional activation
domain [34], and a 29-amino acid extension fused in frame.
However, it lacks the entire C-terminal basic region and leucine
zipper domain (residues 89–494) that function in ATF7-1 and
ATF7-2 as a DNA binding domain/nuclear localization signal
(NLS) and as a dimerization domain respectively [33] (Figure 1B).
It is likely therefore that ATF7-4 exhibits functions that are distinct
from those of the ATF7 full-length (ATF7-FL) isoforms. The
alignment of peptide sequences derived from genomic sequences
available in the databases reveals that the ATF7-4 isoform is
potentially encoded in many mammalian genomes but not in
mouse or rat. Moreover, it exhibits a highly conserved hydropho-
bic domain (HD) in its C-terminal moiety (Figure 1C).
ATF7-4 is ubiquitously but differentially transcribed
To investigate the expression pattern of the ATF7-4 isoform,
cDNAs panels from human tissues and different cell lines were
analyzed by qRT-PCR using primers that are specific of the
different species of ATF7 cDNAs (Table S1). We observed that
ATF7-4 and ATF7-FL (i.e. ATF7-1 and ATF7-2) transcripts are
detectable in all the human tissues and cell lines tested, reflecting a
ubiquitous expression (Figure 2A and B, left panels, and Figure
S2). However, the ATF7-4 transcript is predominantly detected in
brain, heart, kidney, muscle, testis and also in HeLa, A549 and
H1299 cell lines (Figure 2A and B, left panels). As expected, no
ATF7-4 expression was detected in mouse embryonic fibroblasts
(MEF, data not shown). We then assessed the relative ratio of
ATF7-4 mRNA levels compared to those of ATF7-FL in the same
tissues and cell lines. Interestingly, this analysis revealed a rather
strong disparity of the relative accumulation levels of the two
mRNA species, ATF7-4 mRNAs being two to seven times more
abundant in some organs, i.e. kidney, muscle, thyroid, and nearly
absent in pancreas (Figure 2A and B, right panels).
ATF7-4 protein level was next analyzed by western-blot in
HeLa and 3T3 cell extracts (Figure 2C). The monoclonal antibody
used in these experiments was directed against a peptide spanning
residues 96–108, a region unique to the ATF7-4 protein. As
expected, ATF7-4 protein expression was detected in HeLa but
not in mouse 3T3 cell extracts (Figure 2C). Moreover, a specific
siRNA efficiently knocked down ATF7-4. Together, these results
indicate that human ATF7-4 is ubiquitously but differentially
expressed, potentially suggesting a tissue-specific role for this
variant. The high ATF7-4 mRNA and protein levels detected in
HeLa cells led us to study its cellular function in those cells.
ATF7-4 is localized in the cytoplasm
Since ATF7-4 essentially comprises the activation domain of the
ATF7 proteins and lacks their C-terminal dimerization/nuclear
localization signal (NLS) domain, we examined its subcellular
localization compared to those of the ATF7-FL proteins.
Immunofluorescent staining experiments with specific ATF7
antibodies revealed that overexpressed ATF7-4 protein mainly
localizes in the cytoplasm, whereas ATF7-FL proteins are nuclear
in HeLa cells (Figure 3A). In an attempt to map the peptidic
elements mediating ATF7-4 cytoplasmic localization, the hydro-
phobic domain (HD) that is specific to ATF7-4 and absent in
ATF7-FL was fused, either in its wild-type or mutant version, at
the C-terminal end of the eGFP (Figure 3B). In the mutant
derivative, the hydrophobic domain was disrupted by replacing
four leucine and isoleucine residues with alanine residues
(Figure 3B). These eGFP-fusion proteins were then expressed in
HeLa cells, and their localization was assessed by immunofluo-
rescence (Figure 3C). A quantification of the nuclear fluorescence
intensity over the total cell intensity was performed for each
construct (Figure 3D). Control experiments indicated that the
eGFP protein was expressed both in nucleus and cytoplasm
(Figure 3C and D, row 1), whereas it was clearly directed to the
cytoplasm when fused to the ATF7-4 specific domain (Figure 3C
and D, row 2). Moreover, the nuclear localization was rescued by
the mutations in the hydrophobic domain (Figure 3C and D, row
3). These results clearly demonstrate that the ATF7-4 transcription
factor isoform is cytoplasmic, and that this localization is mediated
by its C-terminal hydrophobic domain.
ATF7-4 is phosphorylated and subsequently degraded by
a proteasome-dependent pathway
We have previously demonstrated that both basal and p38b2
MAP kinase-stimulated ATF7-FL transcriptional activities depend
mainly on the phosphorylation of residues Thr51, Thr53 and
Thr112 within the activation domain of the protein, although the
p38b2-mediated phosphorylation is restricted to Thr51 [23]. Since
ATF7-FL proteins and the cytoplasmic variant ATF7-4 share the
same N-terminal part of the activation domain, we investigated the
contribution of the two Thr51 and Thr53 residues in both basal
and p38b2-mediated ATF7-4 phosphorylation. Site-directed
mutagenesis was performed to modify these two residues into
alanine residues, generating the T51A and T53A mutants
(Figure 4A). The wild-type or mutated versions of ATF7-4 were
co-expressed or not with MKK6-activated p38b2 in HeLa cells
and analyzed by western-blotting using specific antibodies. The
monoclonal antibody directed against the C-terminal part of
ATF7-4 specifically recognizes non-phosphorylated ATF7-4
(Figure 4B, upper panel, and data not shown). The phospho-
specific antibodies targeting ATF7 when it is phosphorylated on
Thr51 (pThr51) and Thr53 (pThr53) have been previously
described [23] (Figure 4B, lower panels). In the absence of
activated p38b2, the phosphorylation of Thr53 residue could be
revealed using the pThr53 antibody (Figure 4B, lane 1). However,
no signal was detected with the pThr51 antibody, indicating that,
like the ATF7-FL protein, ATF7-4 is not phosphorylated on
residue Thr51 under these conditions. By contrast, co-expression
of activated p38b2 led to Thr51 phosphorylation (Figure 4B, lane
2). This double phosphorylated form (Thr51/Thr53) was more
efficiently recognized by the pThr53 antibody, as previously
described [23], resulting in an increased signal (Figure 4B, lane 2).
The mutation of each of the two threonine residues affected the
phosphorylation pattern of the ATF7-4 protein (Figure 4B, lanes
3–6). Importantly, the T53A mutation impaired Thr51 phosphor-
ylation (Figure 4B, lane 6), indicating that Thr53 integrity is
required for subsequent Thr51 phosphorylation, as it is the case
for ATF7-FL that exhibits a two-step phosphorylation mechanism
[23]. That the ATF7-4 species detected by the phospho-specific
antibodies correspond to phosphorylated forms is further demon-
strated by their sensitivity to calf intestinal phosphatase (CIP)
treatment and their rescue in presence of EDTA, an inhibitor of
CIP (Figure 4B, lanes 7 and 8). In conclusion, the ATF7-4 protein
is phosphorylated in a two-step manner like ATF7-FL, first on
Thr53 and then on Thr51 by the p38b2 MAP kinase.
We next studied the stability of ATF7-4 and ATF7-FL proteins
by using MG-132, a proteasome 26S inhibitor. ATF7-4 (Figure 4C,
lanes 1–4) or ATF7-FL (Figure 4C, lanes 5–8) proteins were co-
expressed or not with activated p38b2 in HeLa cells in the absence
or presence of MG-132. We then compared the respective
amounts of the non-phosphorylated and phosphorylated ATF7-4
and ATF7-FL proteins in these conditions. After MG-132
ATF7-4 Inhibits ATF7 and ATF2 Activation
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phosphorylated (Figure 4C, lane 2) and p38b2-phosphorylated
(Figure 4C, lane 4) ATF7-4 proteins in cell extracts, clearly
indicating that phosphorylated ATF7-4 is stabilized after protea-
some inhibition. In contrast, no difference could be observed for
non-phosphorylated ATF7-4 (Figure 4C, lanes 1–4, upper panel)
or ATF7-FL (Figure 4C, lanes 5–8), whether phosphorylated or
not, under the same conditions. Thus, it appears that the ATF7-4
isoform is specifically prone to proteasome-dependent degradation
once phosphorylated, in contrast to ATF7-FL.
To further confirm the implication of the proteasome in the
phospho-ATF7-4 degradation, we co-expressed ATF7-4 and
His-tagged ubiquitin in HeLa cells treated with MG-132. His-
tagged proteins, i.e. ubiquitin and ubiquitin-conjugated proteins,
were purified on nickel beads and analyzed by immunoblotting
with specific antibodies. Rabbit antiserum recognizing phosphor-
ylated ATF7-4 (pATF7-4) enabled us to detect a specific pattern of
poly-ubiquitinated phospho-ATF7-4 proteins (Figure 5D, lane 2).
These results demonstrate that phosphorylated ATF7-4 are
substrates for poly-ubiquitination.
Taken together, these results strongly suggest that ATF7-4 is
specifically degraded via the ubiquitin-proteasome 26S pathway
when it is phosphorylated, whereas ATF7-FL is not.
Figure 2. Pattern of expression of ATF7-4 transcript. (A and B) Real-time RT-PCR analysis of ATF7-4 gene expression profile (left panels) (A) in a
24 human tissue-cDNA array and (B) in a selection of human transformed cell lines. Right panels show the ATF7-4 expression relative to that of ATF7-
FL. PBL stands for peripheral blood leucocytes. Data are the average of at least five independent experiments (standard deviations are shown). Data
were normalized to b-actin gene expression. (C) Endogenous ATF7-4 protein was analyzed by western-blotting (WB) with a specific anti-ATF7-4
monoclonal antibody in human HeLa cells and mouse 3T3 fibroblasts. HeLa cells were transfected with either the px-ATF7-4 expression vector or a
control, or specific siRNA targeting ATF7-4. b-actin was analyzed in parallel as a loading control.
doi:10.1371/journal.pone.0023351.g002
ATF7-4 Inhibits ATF7 and ATF2 Activation
PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e23351ATF7-4 downregulates the transcriptional activity of
ATF7-FL and ATF2
We looked for a functional role of ATF7-4 isoform. Since
ATF7-4 and ATF7-FL proteins share the same activation domain,
but are located in two distinct cellular compartments, we tested
whether ATF7-4 could have an effect on ATF7-FL transcriptional
activity or act as a negative regulator form of ATF7-FL. To answer
this question, we assessed the transcriptional activity of ATF7-FL
under various conditions. In order to circumvent a potential
interference of the endogenous ATF proteins, we used an assay
based on a luciferase reporter controlled by Gal4 fusion proteins
[35]. ATF7 and ATF2 N-terminal sequences were fused to the
Gal4 DNA-binding domain (Figure 5A, a). The resulting fusion
proteins were co-expressed in HeLa cells with increasing amounts
of ATF7-4 wild-type (WT) or mutant versions (Figure 5A, b), and
their transcriptional properties were monitored by measuring the
luciferase activity in the cellular extracts. The ATF7-4 T51A
T53A and ATF7-4 C9A T51A T53A derivatives are non-
phosphorylable proteins, while the latter exhibits an additional
mutation in the zinc finger motif that prevents the binding of
different ATF7 partners, among which its TAF12 coactivator [8].
The activity of the Gal4-ATF7(2–82) moiety was clearly inhibited
in the presence of increasing amounts of ATF7-4 WT and to a
lesser extent by ATF7-4 T51A T53A, whereas it was unaffected by
the ATF7-4 C9A T51A T53A protein (Figure 5B).
To determine whether this phenomenon is specific to ATF7 or
has a wider impact, we then analyzed the effect of ATF7-4 on the
transcriptional activity of ATF2 transcription factor, structurally
and functionally related to ATF7. The impact of ATF7-4 on the
transcriptional activities of Gal4-ATF2 and the unrelated Gal4-
Elk1 factor as a control, was assessed by luciferase assays.
Interestingly, ATF7-4 expression resulted in a strong inhibition
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Figure 3. The hydrophobic domain of ATF7-4 controls its cytoplasmic localization. (A and C) Confocal microscopy images of (A) ATF7-FL,
ATF7-4, and (C) eGFP proteins or eGFP-ATF7-4 fusion versions overexpressed in HeLa cells and stained by immunofluorescence with specific
antibodies (central panels). DNA was stained with Hoechst 33258 (left panels). A merge of signals is shown on the right panels. (B–D) Analysis of the
functional role of the ATF7-4 hydrophobic domain. (B and C) The relocalization of eGFP (lane 1) was assessed for eGFP fusion proteins with ATF7-4
hydrophobic domain (HD), either wild type (wt, lane 2) or mutant version (mt, lane 3). In the latter construct, the four conserved hydrophobic
residues (highlighted) were mutated (asterisks) to alanine. Representative confocal images are shown. (D) The fluorescence intensity in the nucleus
(N) over the total cell intensity (N+C) was quantified using ImageJ. The results presented are the average of at least 22 cells analyses for each
condition. Standard deviations and statistical significance by Student t-test are shown: NS=nonsignificant, ***p,0.001. Scale bar: 10 mm.
doi:10.1371/journal.pone.0023351.g003
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no effect on Gal4-Elk1 activity (data not shown). Taken together,
these results demonstrate that ATF7-4 acts as a negative regulator
of the transcriptional activation mediated by members of the
ATF7/ATF2 family.
We next investigated whether ATF7-4 was able to inhibit the
expression of cellular genes whose promoters are regulated
through CRE or TRE elements bound by ATF7 or ATF2
proteins (c-Fos, c-Jun and TGF-b1 genes) [36,37], or by Jun/Sp1
proteins (p21
CIP1 gene) [38]. To this end, ATF7-4 WT or mutant
C9A T51A T53A version were co-expressed with activated p38b2
in HeLa cells treated with MG-132 to avoid any degradation of
ATF7-4. The relative mRNA expression was assessed for these
four genes by real-time quantitative RT-PCR with specific primers
(Table S1). In contrast to ATF7-4 C9A T51A T53A (Figure 5D,
black bars), ATF7-4 WT markedly and significantly reduced the
p38b2-induced expression of c-Fos, c-Jun, and TGF-b1 genes
(Figure 5D, grey bars), whereas both had no effect on the p21
CIP1
gene expression level. These results further emphasize the ability
of ATF7-4 to downregulate the expression of genes controlled by
transcription factors of the ATF7/ATF2 family. The fact that
ATF7-4 only exhibits its interfering effect when its N-terminal zinc
finger motif (a protein-protein interaction domain) is intact
strongly suggests that ATF7-4 could compete for a common
partner that plays a major role in the transcriptional activation
process.
ATF7-4 specifically inhibits ATF7-FL and ATF2
phosphorylation
To decipher the mechanism leading to the inhibition of ATF7-
FL and ATF2 transcriptional activities, we first tested whether
ATF7-4 could have an effect on ATF7-FL expression per se. To this
end, ATF7-FL relative mRNA expression in HeLa cells was
measured by real-time quantitative RT-PCR in the presence of
ATF7-4 WT or its C9A T51A T53A derivative. No significant
differences in ATF7-FL expression level could be detected
(Figure 6A), clearly indicating that ATF7-4 impairs the ATF7-
FL/ATF2 activities by another mechanism than by inhibiting their
own mRNA expression.
The decrease of transcriptional activity could result from either
a downregulation at the protein level or a deficiency in the
phosphorylation process. Thus, the overall level and phosphory-
lation state of ATF7-FL and ATF2 proteins were determined by
western-blotting in HeLa cells co-expressing ATF7-FL or ATF2
with ATF7-4 WT or its mutant version. To clearly delineate the
different species of ATF7-FL/ATF2 proteins, the overall protein
signal and the Thr53/Thr71 phospho-specific signal were merged.
In absence of any activation, c-Jun protein level was stable and
Figure 4. ATF7-4 is phosphorylated and subjected to degradation by a proteasome 26S-dependent pathway. (A) Schematic diagrams
indicating the known phosphorylated residues of ATF7-FL protein and the derived series of ATF7-4 mutants used. (B) The indicated WT or mutant
versions of ATF7-4 were co-expressed with p38b2 and constitutively active MKK6(Glu) in HeLa cells. Cell lysates were either untreated or treated with
calf intestinal phosphatase (CIP), in presence of EDTA where indicated. The analysis was performed by western-blotting (WB) with specific antibodies
as specified to detect non-phosphorylated (ATF7-4) and phosphorylated ATF7-4, either on residues Thr51 (pThr51) or Thr53 (pThr53). (C) ATF7-4
(lanes 1–4) and ATF7-FL (lanes 5–8) were co-expressed with p38b2 and MKK6(Glu) in HeLa cells treated with MG-132 proteasome inhibitor as
indicated. Cell lysates were analyzed by WB with specific antibodies to detect ATF7-4, ATF7-FL and their phosphorylated forms. (D) ATF7-4 was co-
expressed with 6His-Ubiquitin in HeLa cells treated overnight with MG-132. Whole cell extracts (WCE) were purified by a nickel affinity pulldown (Ni-
NTA) and analyzed by WB with specific antibodies to detect the poly-ubiquitinated forms of ATF7-4. The asterisks indicate nonspecific signal.
doi:10.1371/journal.pone.0023351.g004
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PLoS ONE | www.plosone.org 6 August 2011 | Volume 6 | Issue 8 | e23351used as a loading control. Upon ATF7-4 WT expression, we
observed a 60% reduction of the phospho-specific signals and a
concomitant loss of mobility-shifted forms (Figure 6B, lanes 2 and
5), while the overall amounts of ATF7-FL and ATF2 proteins were
only slightly affected. By contrast, the phosphorylation levels of
these two proteins was much less reduced by co-expression of the
ATF7-4 C9A T51A T53A mutant (Figure 6B, lanes 3 and 6).
Thus, ATF7-4 specifically impairs ATF7-FL/ATF2 phosphoryla-
tion on residues Thr53/Thr71 respectively.
To further elucidate the process involved, we tested whether
these phosphorylated forms could be degraded, by repeating the
experiment under a MG-132 treatment. The loss of ATF7-FL
Thr53 phosphorylation was not significantly influenced by this
treatment (Figure 6C), indicating that a proteasome-independent
process is involved.
Furthermore, co-expression of ATF7-4 had no effect on the
subcellular localization of either total or phosphorylated ATF7-FL
species (Figure S3), ruling out any relocation induction.
We have previously demonstrated that phosphorylation and
sumoylation of ATF7-FL are mutually exclusive [23]. It was
therefore of interest to examine whether ATF7-4 induced a
change in the sumoylation status of ATF7-FL. We showed that the
decrease of ATF7-FL phosphorylation achieved by increasing
amounts of ATF7-4 was not paralleled by a concomitant increase
of ATF7-FL sumoylation (Figure S4).
Together, these results clearly demonstrate that ATF7-4 does
not influence ATF7-FL stability or subcellular localization,
whereas it specifically affects the phosphorylation of ATF7-FL/
ATF2 on residues Thr53/Thr71 respectively, which is the first
event leading to their activation.
ATF7-4 binds to a Thr53-phosphorylating kinase in the
cytoplasm
ATF7-FL can be phosphorylated by associated protein kinase
activities under in vitro assay conditions [22,39]. In a search of a
kinase activity that could be associated with the ATF7-4 protein,
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Figure 5. ATF7-4 inhibits the transcriptional activity of ATF7-FL and ATF2. (A–C) (A) (a) The luciferase activity assays were performed by co-
expressing a Gal4-dependent luciferase reporter and Gal4-ATF fusion versions in HeLa cells. Gal4 DNA binding domain (DBD) was fused to the
activation domains (AD) of either ATF7 (B) or ATF2 (C). (A) (b) The transcriptional activities were measured in presence of increasing amounts of co-
expressed ATF7-4 or mutant versions. (B and C) Cell lysates were assayed for luciferase activity and analyzed in parallel by western-blotting (WB) with
specific antibodies. The data of representative experiments are presented (standard deviations are shown). (D) Endogenous ATF7-FL/ATF2
transcriptional activity was measured by a real-time RT-PCR analysis of the expression of known target genes (c-Fos, c-Jun and TGF-b1) or control
(p21
CIP1). p38b2 and MKK6(Glu) were co-expressed in HeLa cells treated with MG-132. Relative gene expression was assessed in absence (control) or
presence of ATF7-4 WT or mutant version. Data were normalized to hypoxanthine-guanine phosphoribosyltransferase (HPRT) gene expression.
Results are the average of three independent experiments. Standard deviations and statistical significance by Student t-test are shown:
NS=nonsignificant, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0023351.g005
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Figure 6. ATF7-4 impairs ATF7-FL/ATF2 phosphorylation by retaining a specific kinase. (A) Endogenous ATF7-FL relative mRNA
expression levels were assessed by real-time RT-PCR in HeLa cells, in presence of overexpressed ATF7-4 WT or mutant derivative. Data were
normalized to hypoxanthine-guanine phosphoribosyltransferase (HPRT) gene expression. Results are the average of two independent experiments.
Standard deviations and statistical significance by Student t-test are shown: NS=nonsignificant. (B and C) The phosphorylation state of
overexpressed ATF7-FL and ATF2 was established in presence of ATF7-4 WT or mutant version, in HeLa cells treated (C) or not (B) with MG-132
proteasome inhibitor. The analysis was performed on total cell extracts by western-blotting (WB) with specific antibodies as indicated. Images of total
ATF7-FL/ATF2 (green channel) and phosphorylated forms (red channel) were merged with LI-COR Odyssey software. c-Jun levels were used as a
loading control. The relative band density of phosphorylated forms was quantified and normalized to c-Jun band density. Results of representative
experiments are shown. (D) HeLa cells overexpressing ATF7-4 or mutant version were treated with MG-132. ATF7-4 and the associated proteins were
immunoprecipitated with anti-ATF7-4 specific antibody, and assayed for a kinase assay with radiolabelled [c-
32P]ATP. The analysis was performed by
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transfected with vectors expressing either ATF7-4 WT protein or
the T51A T53A derivative. The immunoprecipitates were then
incubated under in vitro kinase assay conditions. In vitro
phosphorylation of ATF7-4 WT was detected (Figure 6D, lane
2), while no labelling of the T51A T53A mutant was found
(Figure 6D, lane 1), indicating that a protein kinase targeting
Thr51 and/or Thr53 was immunoprecipitated with ATF7-4.
Thus, a protein kinase is associated to ATF7-4 in the cytoplasm.
To address whether this phenomenon is responsible for ATF7-4
interference in ATF7-FL phosphorylation, we decided to relocate
ATF7-4 and examine whether it was still phosphorylated and able
to compete for ATF7-FL phosphorylation. We thus constructed
pIX-ATF7-4 fusion proteins with the central region of ATF7-4
(residues 27–79 of either the WT or T51A T53A version) inserted
within the sequence of adenovirus protein IX (pIX) (Figure 6E).
pIX is a protein that contributes to the Ad5-induced reorganiza-
tion of the host cell nuclear ultrastructure by inducing the
formation of nuclear inclusions into which proteins can be
relocated [40,41]. pIX can also be used as a platform for the
incorporation of heterologous proteins [42]. ATF7-FL was co-
expressed with the pIX-ATF7-4 fusion proteins and activated
p38b2 MAPK in HeLa cells, and their phosphorylation states were
analyzed by western-blot. We could detect pIX-ATF7-4 phos-
phorylation on Thr53 (Figure 6E, lane 4), demonstrating that this
central region of ATF7-4 functions as a docking site for an
associated kinase. As expected, the expression of pIX-ATF7-4 WT
resulted in a decrease of ATF7-FL phosphorylation on Thr53
(Figure 6E, lane 4), confirming that ATF7-4 competes with ATF7-
FL for the binding to the kinase that specifically phosphorylates
the Thr53 residue in the nucleus. Interestingly, the T51A T53A
non-phosphorylable mutant had the same effect (Figure 6E, lane
6), indicating that it is also able to associate to this kinase, in
contrast to the C9A T51A T53A derivative further mutated in the
zinc finger interaction motif.
Altogether, these results suggest that ATF7-4 inhibits ATF7-
FL/ATF2 phosphorylation and subsequent activation by retaining
a Thr53/Thr71-specific kinase in the cytoplasm.
Discussion
This study extends our previous comprehension of the
molecular mechanisms leading to the regulation of the transcrip-
tional activation of the ATF7/ATF2 transcription factors family.
We identified a short alternatively spliced variant of ATF7 that
encodes a cytoplasmic protein, ATF7-4. This protein prevents
ATF7-FL and ATF2 activation, very likely by retaining in the
cytoplasm the kinase responsible for the first ATF7-FL/ATF2
phosphorylation event. When ATF7-4 gets phosphorylated, it is
poly-ubiquitinated and degraded by a proteasome 26S-dependent
pathway. We propose that the sequestered kinase is subsequently
released, that it enters into the nucleus and phosphorylates the
ATF7-FL/ATF2 proteins. As previously described, this priming
phosphorylation enables the recruitment of p38 kinases for ATF7-
FL/ATF2 activation, which promotes their association to pre-
initiation complexes on promoters and transcription of their target
genes (Figure 7) [23]. In spite of its relatively low level of
expression due to its protein instability, ATF7-4 is highly
conserved in mammalian species (except mouse and rat)
(Figure 1C) and expressed in a wide range of tissues (Figure 2).
Considering its sensitivity to proteolytic degradation (Figure 4C
and D) and its subcellular localization (Figure 3), we are confident
that ATF7-4 plays an important role in the control of
transcription.
ATF7-4 is a specific variant resulting from the ATF7 gene
expression that has no equivalent in the ATF2 gene. Although
human ATF7 and ATF2 genes map on different chromosomes
(ATF7 12q13; ATF2 2q32), the analysis of their genomic
organization in terms of intron/exon distribution indicates that
both genes have a similar structure and may have arisen by
duplication of a common precursor. However, their intronic
sequences between exons 4 and 5 are completely different. The
ATF7 exon 4, in contrast to its ATF2 counterpart, is adjacent to
an additional alternative exon (exon 4a) containing an open-
reading frame that is followed by a polyadenylation sequence
(AATAAA), giving rise to a functional messenger encoding ATF7-
4 protein. Nevertheless, the molecular mechanism leading to exon
4a inclusion and ATF7-4 generation remains unclear. Based on
various examples of pre-mRNA 39 end processing regulation,
different mechanisms of action have been proposed, including a
kinetic competition between the poly(A) signal recognition, splicing
and transcription, directly correlated with the rate of their
respective machinery assembly [43,44,45]. As a result, ATF7-4
encompasses the N-terminal moiety of the ATF7 activation
domain fused in frame to a specific C-terminal hydrophobic
domain (Figure 1B and C), the latter mediating its cytoplasmic
localization (Figure 3). Furthermore, bioinformatic analyses
indicate that this domain shares all the characteristics of a
transmembrane helix [46], the N-terminal part of the protein
being in the cytoplasm. These data are consistent with the fact that
we isolated the TRAPalpha/SSR1 protein as an ATF7 activation
domain-interacting partner in a yeast two-hybrid screening (B.
Chatton, unpublished). The SSR1 protein is a single-spanning
membrane protein of the endoplasmic reticulum (ER) that is found
in proximity to nascent polypeptide chains translocating across the
membrane [47]. Although the ability of ATF7-4 to anchor in
cytosolic membranes with the help of SSR1 has not yet been
demonstrated, it is tempting to speculate that this process might
contribute to the control of ATF7-4 subcellular localization under
specific conditions.
Tissue-specific differential splicing or promoter usage also give
rise to ATF2 variants, but none of them exhibits a dominant
negative activity. Most of these variants are ubiquitously
expressed, although some are particularly enriched in specific
tissues. Three ATF2 isoforms are expressed in murine T-cells:
CRE-BP1, CRE-BP2 and CRE-BP3. Although these isoforms
differ by N-terminal or internal residues, they all retain the bZIP
domain, suggesting that their transcriptional activity is conserved,
even if their regulation is intrinsically different [48,49]. Another
ATF2 splicing variant is expressed in myometrial tissues during
pregnancy/labor (GenBank: AY029364.1) [50]. ATF2-small
(ATF2-sm) only comprises the first two and last two exons, lacking
therefore the most part of the functional domains, i.e. the sequence
encompassing the two threonine residues 69 and 71 of the
activation domain and the bZIP domain. Nevertheless, it was
intriguingly described to exhibit a CRE-binding activity and to be
autoradiography (top panel) and WB (bottom) in parallel. The white arrow indicates radiolabelled ATF7-4. (E) The phosphorylation state of
overexpressed ATF7-FL was analyzed in presence of pIX (a) or pIX-ATF7-4 fusion proteins with the docking site of ATF7-4 for kinases, either WT (b) or
mutant version (c). HeLa cells were co-expressed with p38b2 and MKK6(Glu). Cell lysates were analyzed by WB to detect the specific phosphorylation
of ATF7-FL (two upper panels) and pIX-ATF7-4 fusion proteins (two lower panels).
doi:10.1371/journal.pone.0023351.g006
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length ATF2 [50]. Yet, no inhibitory effect has been associated to
this variant. Therefore, among all these described isoforms, ATF7-
4 is the only negative regulator form of the ATF7-FL/ATF2
transcription factors family characterized to date, further high-
lighting its considerable importance.
The ATF7-4 phosphorylation process is consistent with the
previously described ATF7-FL dual phosphorylation (Figure 4B)
[23]. Indeed, this two-step mechanism also involves a priming, yet
unidentified, kinase activity that phosphorylates residue Thr53. It
is followed by the secondary phosphorylation of Thr51 by
activated p38b2 kinase. Our data suggest that ATF7-4 could
sequester in the cytoplasm the unknown priming kinase thereby
preventing ATF7-FL and ATF2 phosphorylation of Thr53 and
Thr71 (Figure 6). It has been well documented that ATF2 is
activated through phosphorylation on threonine residues 69/71 by
stress-activated protein kinases JNK or p38 [17,18,51,52,53].
ATF2 is also activated by growth factors via the Ras-MEK-ERK
pathway, for initial Thr71 phosphorylation, in concert with the
RalGDS-Src-p38 kinases, for subsequent Thr69 phosphorylation,
thus involving cooperation between distinct signaling pathways for
its transcriptional activation [19,20,21]. However, based on the
effects of specific inhibitors (U0126 or SB203580) and the results of
transfection experiments in Jnk1 and Jnk2 deficient fibroblasts, we
ruled out that ERK or JNK MAP kinases could be involved in the
first ATF7-FL phosphorylation event on residue Thr53 [23]. It
appears therefore that a distinct priming kinase activity is
responsible for this phosphorylation event in both ATF7 and
ATF2.
The present study offers clear evidence that ATF7-4 functions
as a negative regulator counterpart of ATF7-FL and ATF2
activities. Such entities have provided substantial insights into the
molecular mechanisms of action of a number of protein families,
including hormone or growth factor receptors and oncogenes. In
agreement with our findings, Z. Ronai and collaborators have
demonstrated the ability of a 51-residue polypeptide derived from
the ATF2 transactivating domain (ATF2
50–100) to alter melanoma
growth and metastasis capacity in vivo [12,54,55]. Given the strong
homology between ATF2 and ATF7, ATF7-4 might thus be
considered as the cellular counterpart of this synthetic peptide.
ATF7-4 and ATF2
50–100 peptide share functional characteristics,
including their cytoplasmic localization, as well as the ability to
downregulate ATF2 transcriptional activity and to associate with
kinases [12,55]. In addition, the ATF2
50–100 peptide has been
shown to induce the relocation of ATF2 and c-Jun proteins to the
cytoplasm and a concomitant increase of c-Jun expression, without
significantly altering the phosphorylation of ATF2 [54]. However,
in presence of ATF7-4, we observed neither a relocation of ATF7-
FL and c-Jun nor an accumulation of the latter protein in HeLa
cells under our experimental conditions (Figure S2). Thus, ATF7-4
and ATF2
50–100 peptide both control ATF2 activity, but distinct
mechanisms of action may be involved. This discrepancy may be
Figure 7. Model illustrating the regulatory role of ATF7-4. (A) Under resting conditions, ATF7-4 retains in the cytoplasm a kinase (K) that is
able to phosphorylate ATF7-FL/ATF2 on Thr53/Thr71 respectively, preventing any transcription activity on their target genes. (B) The stimulus-
induced phosphorylation of ATF7-4 promotes its poly-ubiquitination and degradation. (C) Our model proposes that the kinase is subsequently
released, enters the nucleus and phosphorylates ATF7-FL/ATF2. (D) This first phosphorylation event is necessary for stress-activated p38 recruitment
and ATF7-FL/ATF2 phosphorylation on Thr51/Thr69 respectively. The double phosphorylated forms associate efficiently with preinitiation complex
(PIC) and are transcriptionally active.
doi:10.1371/journal.pone.0023351.g007
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domains, i.e. the zinc-finger motif and the C-terminal hydropho-
bic domain, which are implicated in protein-protein interactions
and the control of ATF7-4 subcellular localization respectively.
The mechanism that we uncovered enables us to delineate the
docking site of ATF7 for kinases. We found that the ATF7-4 (27–
79) domain is able to interact with the priming kinase whether the
WT or T51A T53A versions were used (Figure 6E). These results
indicate firstly that the priming kinase docking site is located
within the 27–79 region of ATF7-4, a domain matching precisely
the ATF2
50–100 peptide, and secondly that the two threonine
residues are not essential for the binding. Further corroborating
our study, other proteins have been described to interact with
MAPK in the cytoplasm and prevent their translocation into the
nucleus. For instance, PEA15 and protein tyrosine phosphatase
PTP-SL, which retain MAPK in the cytoplasm [56,57], or the
regulatory protein TAB1 that competes with MKK3 for p38
interaction, binds to p38 and prevents its nuclear localization [58].
The phosphorylation of ATF7-4 induces its degradation
(Figure 4). The general principles of phosphorylation-dependent
ubiquitination are clearly understood. Phosphorylation on specific
residues can result in the generation of a motif, known as
phosphodegron, which is specifically recognized by F box proteins
within E3 ligase complexes (for a review see [1]). However, the
mechanism governing phosphorylation-dependent degradation of
ATF7-4 remains unclear. Its phosphorylation by the priming
kinase may either activate a specific cytosolic E3 ligase responsible
for ubiquitin conjugation or promote its recognition by the E3
ligase while creating a phosphodegron. The involvement of a
cytoplasm-specific E3 ligase could explain why under these
conditions phosphorylated ATF7-4 is degraded whereas nuclear
ATF7-FL and ATF2 are not. Moreover, previous studies have
provided evidence that under resting conditions, nuclear ATF2 is
unstable and degraded. Upon stress induction, this protein is
phosphorylated and activated, leading to its stabilization and
protection from degradation until its subsequent downregulation
by phosphatases [59,60]. This model is consistent with our
findings, suggesting that phosphorylation induces a switch from
ATF7-4 primacy to ATF7-FL/ATF2 action.
In summary, our results demonstrate in our cellular model
(HeLa cells) a novel important role for a cytoplasmic isoform of a
transcription factor in inhibiting the activity not only of its nuclear
counterpart (ATF7-FL), but also of a distinct one (ATF2). We
provide novel mechanistic insights into the temporal and spatial
regulation of these transcription factors, through the control of
their specific kinase location. The kinases remain however to be
identified. It will also be of interest to examine whether the
cytoplasmic interaction of this kinase with ATF7-4 also interferes
with other cellular processes, which would further extend the
functional importance of ATF7-4.
Materials and Methods
Expression vectors
The recombinant human ATF7 isoforms used in this study are
ATF7-4 and ATF7-1, the latter referred to as ATF7-FL, keeping
the amino acid coordinates of the largest protein (ATF7-3, 494
residues) [8]. The full sequences of the ATF7-4 transcript (787
nucleotides) and protein (117 amino acids) have been given
the GenBank and Swissprot accession numbers BC042363
and Q8IVR8 respectively. The pG4-ATF7(2–82) and pG4-
ATF2(19–96) plasmids encode the DNA-binding domain of the
yeast Gal4 protein fused to the human activation domain of either
ATF7-FL (amino acids 2–82) or ATF2 (amino acids 19–96), as
previously described [39,52]. The (17m5)-TK-Luc reporter [61]
contains the luciferase gene driven by the thymidine kinase
promoter and five Gal4 binding sites. The cDNA of ATF7-FL,
ATF7-4, ATF2 and mutant versions were also inserted into the
pXJ plasmid, under the control of the cytomegalovirus (CMV)
promoter [62], generating the px-ATF series. The pXJ-pIX-
ATF7-4 vector and derivative encode the pIX adenoviral (Ad 5)
protein fused to a central moiety of ATF7-4 (amino acids 27–79).
The peGFP-ATF7-4 vector and mutant version encode the eGFP
protein fused to the C-terminal part of ATF7-4 (amino acids 89–
117). Plasmids encoding dominant active MKK6 [referred to as
MKK6(Glu)] [18], p38b2 [63], and 6His-Ubiquitin [64] were
kindly provided by J. Raingeaud, J. Han and M. Treier
respectively. Point mutations and deletions were generated by
oligonucleotide-directed mutagenesis using Pfu DNA polymerase
(Fermentas), PCR amplification and restriction endonuclease
digestion of the appropriate DNA fragments. All constructs were
verified by DNA sequencing.
Cell culture, RNA interference, transfection, extract
preparation and fractionation
HeLa, H1299, U-2 OS and MEF cells were grown as
monolayers in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 4.5 g/L glucose and 10% fetal calf serum
(FCS) [5] [65] [39] [66]. Raji [67], 501Mel [68] and HTR-8/
SVneo [69]cells were maintained in RPMI 1640 medium
containing 10% FCS. HEK[70], HCT 116 [71], and HeLa-
SUMO cells were grown in DMEM supplemented with 1 g/L
glucose and FCS, 10%, 7.5% and 5% respectively. A549 [72] and
1205Lu cells were cultured respectively in DMEM/F12 medium
supplemented with 10% FCS, and in complete tumor medium
W489, a 3:1 mixture of MCDB153 and Leibovitz L15
supplemented with 4% FCS. HeLa-SUMO cells, constitutively
expressing high levels of 6His:Myc:epitope-tagged human SUMO-
1 protein, were kindly provided by P. O’Hare [73]. HTR-8/
SVneo, 1205Lu [74] and 501Mel cells were kindly provided by V.
Sapin, G. Mengus and I. Davidson respectively.
Cells were transiently transfected using TransITH-LT1 reagent
(Mirus Bio Corporation, Euromedex) according to the manufac-
turer’s protocol. After 28 h, cells were harvested in phosphate-
buffered saline (PBS) and resuspended in RIPA buffer [150 mM
NaCl, 20 mM Tris-HCl pH 7.8, 0.1% SDS, 1% Triton X-100,
0.5% sodium deoxycholate, 1 mM dithiothreitol [DTT], 1 mM
sodium orthovanadate, Protease Inhibitor Cocktail (Sigma)]. After
30 min on ice, the resulting crude suspension was cleared by
centrifugation for 15 min at 10,000 g. Cells at 30–50% confluence
were transfected with 15 nM of control or specific siRNA (siATF7-
4, 59-AA-CATGGGCTTAGTAGAGTAA-AA-39, Ambion, Aus-
tin, TX) using HiPerFect reagent (Qiagen) and harvested after
48 h.
In Figures 6B and C, cellular proteins were extracted by boiling
cell pellets 30 min in SDS sample buffer [125 mM Tris-HCl
pH 6.8, 40% glycerol, 8% SDS, 200 mM DTT, 0.02% bromo-
phenol blue] and the lysates were then homogenized by a 4 min-
sonication in a cold water bath (BioruptorH Next Gen,
Diagenode).
For the phosphatase treatment, cell lysates were incubated for
1 h at 37uC with 10 units of calf intestinal phosphatase (CIP, New
England Biolabs) in 50 mL of reaction buffer [50 mM Tris-HCl
pH 7.8, 50 mM KCl, 10% glycerol and 1 mM DTT] supple-
mented with 50 mM EDTA for CIP inhibition where indicated.
Cells treated with proteasome inhibitor were incubated for 2 h
with 30 mM MG-132 (Calbiochem).
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in lysis buffer [10 mM Hepes pH 7.9, 1.5 mM MgCl2, 10%
glycerol, 0.1% Nonidet P-40, 0.1 mM EGTA, 0.5 mM DTT,
1 mM N-ethyl-maleimide (NEM), Protease Inhibitor Cocktail]
as described [75]. Lysates were centrifuged and the supernatant
was retained (cytoplasmic fraction). The remaining pellets were
incubated for 1 h on ice in lysis buffer supplemented with 300 mM
NaCl. The resulting lysates were cleared by centrifugation
(nuclear/euchromatin fraction). The pellets were digested for
30 min at 30uC with 300 units DNase (Sigma) in digestion buffer
[20 mM Tris-HCl pH 7.4, 5 mM MgCl2, 250 mM sucrose,
1 mM NEM, Protease Inhibitor Cocktail]. Extracts were centri-
fuged and the supernatants were retained (heterochromatin
fraction).
Luciferase assay
HeLa cells (2.10
5 cells per well in six-well plates) were
transfected using ExGen 500 reagent (Euromedex) with a mixture
containing 0.5 mg of the luciferase reporter, 0.2 mg of the pG4-
ATF expression vector, and up to 0.3 mg of the px-ATF7-4
plasmid. The total amount of DNA was adjusted to 1 mg with
empty vector. After 24 h, cells were washed in PBS and incubated
for 30 min in lysis buffer [1% Triton X-100, 25 mM glycyl-glycine
pH 7.8, 15 mM MgSO4, 4 mM EGTA]. The resulting cell lysate
was assayed for luciferase activity (normalized by protein
concentration) using a Berthold Centro LB 960 luminometer as
previously described [76,77]. At least two independent transfec-
tions were carried out in triplicate and the results always agreed
within 10%. Error bars show standard deviations (n=3).
Antibodies
A rabbit antiserum directed against ATF7FL or ATF7-4
(epitope 42–60) with high affinity for phosphorylated threonine
51 and threonine 53 (pATF7), and monoclonal antibodies
specifically recognizing ATF7-FL isoforms (ATF7-FL, 2F10) or
phosphorylated ATF7 on residues threonine 51 (pThr51, 2H1),
threonine 53 (pThr53, 1H9) and threonine 112 (pThr112, 2F3)
have been previously described [23,39]. To generate specific anti-
ATF7-4 monoclonal antibodies, a peptide [KKLVVFRPRLFLL]
corresponding to amino acids 96–108 was synthesized, coupled to
ovalbumin as a carrier protein and used for mouse immunization.
Immunization and monoclonal antibody production were essen-
tially as reported by [78]. The specificity of the selected antibodies
was verified by comparing their immunoreactivity against ATF7-4
versus ATF7-FL as previously described [23,79]. These monoclo-
nal antibodies directed against the C-terminal part of ATF7-4
specifically recognize non-phosphorylated ATF7-4 (Figure S1).
Mouse anti-GFP (2A3), mouse anti-Gal4 (3GV2) and rabbit anti-
pIX [80] antibodies have been previously described. Rabbit anti-c-
Jun (H-79), mouse anti-ATF2 (F2BR1) and goat anti-p38ß2 (C-16)
antibodies were purchased from Santa Cruz Biotechnology.
Rabbit antiserum specifically recognizing phosphorylated ATF2
(pATF2) and rabbit anti-ubiquitin were obtained from Abcam
(ab28848) and Sigma (U5379) respectively. Anti-SUMO-1,
-Paxillin, -Lamin and -HP1 antibodies were kindly provided by
J.S. Seeler and A. Hamiche.
Ni-NTA agarose affinity purification,
immunoprecipitation and western-blotting
Ni-NTA agarose affinity purification and immunoprecipitations
were carried out as previously described [23] [8]. For western-
blotting, proteins were electrotransferred onto nitrocellulose and
reacted with specific primary antibodies (see above). Bound
antibodies were detected with IRDye800-conjugated anti-mouse
(green channel) and IRDye700-conjugated anti-rabbit (red
channel) secondary antibodies (ScienceTec). Membranes were
scanned with the LI-COR Odyssey infrared imaging system. Anti-
mouse and anti-rabbit signals were merged with the Odyssey v3.0
software (LI-COR Biotechnology, ScienceTec). In all cases, at
least three independent transfections were carried out and the
results always agreed within 10%. The results of typical
experiments are shown in the figures.
Quantitative RT-PCR
The tissue-specific expression pattern of ATF7-4 was investi-
gated by quantitative PCR on a RapidScan
TM gene expression
cDNA panel (OriGene Technologies) containing cDNA from 24
different human tissues normalized to b-actin gene expression. In
the other experiments, total RNA was extracted using TRIzolH
reagent (Invitrogen). Reverse-transcription was performed with
1 mg of total RNA using AMV reverse-transcriptase (Fermentas)
and random hexamer primers as specified by the manufacturer.
Total RNA of WRO and BCPAP thyroid cell lines were kindly
provided by C. Ferraro-Peyret. Quantitative real-time PCR was
performed with 10 ng of cDNA template on the StepOne Plus
TM
system (Applied Biosystems, Life Technologies) according to
the manufacturer’s protocol, using Power SYBRH Green and
TaqManH Universal PCR Master Mixes (Applied Biosystems).
The sequences of the TaqManH probes designed for specific
ATF7-FL and ATF7-4 amplification, and the primer pairs used
are shown in Table S1. Data were normalized to b-actin or
hypoxanthine-guanine phosphoribosyltransferase (HPRT) gene
expression. Results shown are representative of at least two
independent experiments performed at least in triplicate. Error
bars show standard deviations (n=3). Statistical significance was
determined by using Student t-tests.
Immunofluorescence staining and confocal imaging
Immunofluorescence experiments were carried out as previously
described [81]. Briefly, HeLa cells were grown on a Lab-TekH
Chamber Slide (Nunc) and fixed with 4% paraformaldehyde, 28 h
after transfection. Cells were then permeabilized with 0.5% Triton
X-100 in PBS and aspecific sites were saturated with 20% fetal calf
serum in PBST [0.1% Triton X-100 in PBS]. Cells were incubated
with specific primary antibodies diluted in PBST and directed
against ATF7-FL (2F10), ATF7-4 (rabbit antiserum) and GFP
(2A3). Three PBS washes were performed before incubating the
cells with Alexa 488- or Cy3-conjugated anti-rabbit or mouse
secondary antibodies (Molecular Probes, Invitrogen) diluted in
PBST. Nuclei were counterstained with Hoechst 33258 dye
(Sigma) and the preparations were mounted in ProLongH Gold
medium (Invitrogen). Cells were analyzed by confocal laser-
scanning microscopy (Leica). Quantification of nuclear and total
fluorescence intensities was performed using ImageJ on at least 22
images per condition. Error bars show standard deviations (n=22).
Statistical significance was determined by using Student t-tests.
Kinase assay
ATF7-4 and the associated proteins were immunoprecipitated
with the monoclonal anti-ATF7-4 antibody. The proteins
adsorbed to the protein G-sepharose beads were incubated for
40 min at 30uCi n4 0mL of kinase buffer containing 20 mCi of
[c-
32P]ATP (3000 Ci/mmol), 50 mM Tris-HCl pH 7.5, 10 mM
MgCl2, 0.1 mM EGTA and 1 mM DTT. Cold ATP (1 mM)
was added for the last 10 min to catalyze the reaction. The beads
were then washed twice with the same buffer but lacking the
radiolabelled nucleotide. Proteins were then dissociated by boiling
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polyacrylamide gel electrophoresis (PAGE) [82] and electrotrans-
ferred to a nitrocellulose membrane. The
32P-labelled proteins
were revealed by autoradiography and total proteins were
analyzed by western-blotting as described [39].
Supporting Information
Figure S1 Characterization of the specificity of anti-
ATF7-4 antibodies. ATF7-4 was overexpressed in HeLa cells as
indicated. Cell lysates were immunoprecipitated (IP) with different
antibodies recognizing ATF7-4. Affinity-purified proteins were
then analyzed by western-blot (WB) using anti-ATF7-4 or anti-
pThr53 antibodies. Rabbit antiserum and anti-pThr51, anti-
pThr53 monoclonal antibodies (lanes 2, 5 and 6 respectively)
specifically recognize phosphorylated forms of ATF7-4, whereas
the anti-ATF7-4 monoclonal antibody targets the non-phosphor-
ylated form (lane 3). The anti-ATF7 Nt antibody directed against
the N-terminal moiety of ATF7 was used as a control to facilitate
the characterization.
(EPS)
Figure S2 Pattern of expression of ATF7-FL transcripts.
Real-time RT-PCR analysis of ATF7-FL gene expression profile
(A) in a 24 human tissue-cDNA array and (B) in a selection of
human transformed cell lines. (A) PBL stands for peripheral blood
leucocytes. (B) Data are the average of at least five independent
experiments (standard deviations are shown). Data were normal-
ized to b-actin gene expression.
(EPS)
Figure S3 ATF7-FL subcellular localization is not affect-
ed by ATF7-4. ATF7-FL was overexpressed in HeLa cells in
presence of ATF7-4 as indicated. Lysates were fractionated into
cytoplasm, nucleus/euchromatin and heterochromatin fractions,
which were further analyzed by western-blot (WB). Images of total
ATF7-FL (green channel) and phosphorylated forms (red channel)
were merged with LI-COR Odyssey software. c-Jun, Lamin A/C,
Paxillin and HP1a/b were used as loading and fractionation
controls.
(EPS)
Figure S4 ATF7-FL sumoylation is not impaired by
ATF7-4. (A) Schematic representation indicating the location of
the consensus sumoylation site of ATF7-FL and the SUMO
modification-defective mutant used (asterisk). (B) ATF7-FL or
mutant version and an increasing amount of ATF7-4 were co-
expressed in HeLa-SUMO cells. Cell lysates were immunopre-
cipitated with anti-ATF7-FL specific antibody and analyzed by
western-blot (WB). The three upper panels are images of
sumoylated ATF7-FL (green channel), total sumoylated proteins
(red channel) and the overlay. In the three lower panels, images of
total ATF7-FL (green channel) and phosphorylated forms (red
channel) were merged. The overlays were performed with LI-
COR Odyssey software.
(EPS)
Table S1 Primers and TaqMan probes used for real-time RT-
PCR.
(EPS)
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